Mega CapHealthcareDividend

BMY — Bristol-Myers Squibb Company

Pharmaceuticals · Founded 1887 · New York, New York · CEO: Christopher Boerner

Bristol-Myers Squibb is a global biopharmaceutical company focused on serious diseases including oncology, hematology, cardiovascular, and immunology. Its acquisition of Celgene in 2019 for $74 billion dramatically expanded BMS into blood cancer treatments, adding Revlimid, Pomalyst, and Abraxane. BMS also markets Opdivo (cancer immunotherapy), Eliquis (anticoagulant, co-marketed with Pfizer), and Orencia (rheumatoid arthritis). The company faces significant patent cliffs as Revlimid generic competition accelerates.

How Bristol-Myers Squibb Company Makes Money

Oncology drug sales (Revlimid, Pomalyst, Abraxane, Opdivo, Yervoy) for hematology and solid tumors

Eliquis anticoagulant sales split with Pfizer across cardiovascular patients

Immunology therapies including Orencia and Zeposia

Licensing milestones and royalties from collaboration agreements

Key Metrics Investors Watch

Revlimid revenue trajectory as generic competition accelerates post-patent
Opdivo and Yervoy cancer immunotherapy market share vs. Merck Keytruda
Eliquis market retention vs. generic apixaban competition
Pipeline progression in CAR-T, protein degraders, and next-generation oncology
Debt reduction pace from Celgene acquisition leverage

Competitive Advantages

Opdivo plus Yervoy combination immunotherapy provides a differentiated cancer treatment option
Eliquis is a leading anticoagulant with billions in annual sales and strong physician loyalty
Celgene acquisition transformed BMS into a hematology leader with the Revlimid franchise
Strong capital allocation discipline with focus on debt paydown and targeted pipeline acquisitions

Key Risks

Revlimid generic competition significantly pressures the top revenue product
Opdivo faces fierce competition from Merck's Keytruda in cancer immunotherapy
Heavy debt load from Celgene acquisition limits financial flexibility
Multiple patent expirations over 2025-2030 create a revenue cliff similar to Pfizer

Dividend & Capital Return

Bristol-Myers Squibb maintains a substantial quarterly dividend, supported by strong cash flows from its established drug portfolio despite revenue headwinds.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What is Opdivo?

Opdivo (nivolumab) is Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor cancer immunotherapy. It is approved for treatment of dozens of cancers either alone or in combination with Yervoy (ipilimumab). It competes directly with Merck's Keytruda. This is educational content, not financial advice.

What happened when BMS acquired Celgene?

BMS acquired Celgene in 2019 for $74 billion, gaining the blockbuster blood cancer drug Revlimid along with a pipeline of hematology and oncology assets. The deal dramatically expanded BMS's revenue base but added significant debt that management has been paying down. This is educational content, not financial advice.

Does Bristol-Myers Squibb pay a dividend?

Yes, BMS pays a quarterly dividend and has a long history of returning cash to shareholders. The dividend yield is typically above the S&P 500 average, reflecting the company's mature cash-flow profile. This is educational content, not financial advice.

What is the Revlimid patent cliff?

Revlimid (lenalidomide) was one of the best-selling cancer drugs in history before losing exclusivity protection, allowing generic competition to enter the market and erode BMS's revenue significantly. This was a central concern for investors in recent years. This is educational content, not financial advice.

How does BMY compare to Merck?

Both compete heavily in oncology immunotherapy, with BMY's Opdivo and MRK's Keytruda as direct rivals. Keytruda has achieved higher market share and approval in more cancer indications. Merck also has the Gardasil HPV vaccine franchise, providing additional revenue diversity. This is educational content, not financial advice.

Related Stocks

JNJ

Johnson & Johnson

Healthcare

Johnson & Johnson is a global healthcare company operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Following the spin-off of its consumer health division as Kenvue in 2023, JNJ is now focused on higher-growth, higher-margin healthcare segments.

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

PFE

Pfizer Inc.

Healthcare

Pfizer is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, immunology, rare diseases, vaccines, and hospital medicines. The company became globally prominent during the COVID-19 pandemic through its co-developed mRNA vaccine (Comirnaty) with BioNTech and antiviral pill Paxlovid. Post-pandemic, Pfizer has focused on restoring growth through acquisitions including Seagen (oncology) and deploying its substantial cash reserves. The company faces significant patent cliffs on several major drugs in the late 2020s.

AMGN

Amgen Inc.

Healthcare

Amgen is one of the world's largest biotechnology companies, pioneering the use of recombinant DNA technology to develop medicines for serious illnesses. Its portfolio spans oncology (Blincyto, Lumakras), cardiovascular (Repatha), bone health (Prolia, XGEVA), and inflammatory diseases (Otezla, Enbrel). Amgen has been expanding into biosimilars and acquired Horizon Therapeutics in 2023 to add rare disease therapies. The company generates among the highest profit margins in the pharmaceutical industry.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.